GlassScriptPhysician profile
Shirley J Bleak
NPI 1124197512
$2,158.16
in general payments reported to CMS, 2019-2025
28 companies · $597 in 2025
The $597 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $247 · 2022: $118 · 2023: $406 · 2024: $790 · 2025: $597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Education: $299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.88 |
| Education | $298.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $471.38 | 2021-2025 | Rybrevant, Carvykti, Erleada |
| Astrazeneca Pharmaceuticals LP | $270.90 | 2021-2024 | Enhertu, Imfinzi, Calquence |
| Pfizer INC. | $206.15 | 2023-2025 | |
| Seagen INC. | $197.65 | 2021-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $121.71 | 2022-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $112.78 | 2022-2024 | Zejula, Jemperli, Ojjaara |
| Daiichi Sankyo INC. | $107.36 | 2021-2025 | Enhertu |
| Emd Serono, INC. | $96.28 | 2024-2025 | |
| Abbvie INC. | $47.79 | 2024-2025 | |
| Eisai INC. | $47.15 | 2024-2025 | |
| Genmab U.S., INC. | $43.07 | 2023-2024 | Tivdak |
| Gilead Sciences, INC. | $41.72 | 2024-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $39.25 | 2024 | |
| Lilly USA, LLC | $36.98 | 2023-2024 | Verzenio, Retevmo, Jaypirca |
| Astellas Pharma US INC | $32.08 | 2022-2024 | Ambisome |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $30.25 | 2023 | |
| Amgen INC. | $28.93 | 2023 | Kyprolis |
| Genentech USA, INC. | $28.12 | 2023 | Tecentriq |
| Stemline Therapeutics INC. | $24.62 | 2025 | Orserdu |
| Deciphera Pharmaceuticals INC. | $24.47 | 2025 | Tgct, Qinlock |
| Beigene USA, INC. | $24.06 | 2023 | Brukinsa |
| Array Biopharma INC | $22.95 | 2025 | Braftovi, Lorbrena, Tukysa |
| Rigel Pharmaceuticals, INC. | $20.68 | 2023 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $20.11 | 2025 | Keytruda |
| Novocure INC. | $16.19 | 2025 | Optune Lua (Novottf-200t) |
| Exelixis INC. | $15.91 | 2025 | Cabometyx |
| Morphosys, US INC. | $14.85 | 2024 | Monjuvi |
| Celgene Corporation | $14.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shirley Bleak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.